M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Inheritance of osmotic adjustment to water stress in three grain sorghum crosses
TL;DR: Populations of recombinant inbred lines were developed and characterised for osmotic adjustment for two of the crosses and will be used to conduct experiments which test hypotheses about the contribution of the high-osmotic-adjustment genes to the grain yield of sorghum under a range of water-stress conditions.
Journal ArticleDOI
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative “Superbugs” Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators
Maytham Hussein,Elena K. Schneider,Alysha G. Elliott,Mei-Ling Han,Felisa Reyes-Ortega,Faye C. Morris,Mark A.T. Blastovich,Raad Jasim,Bart J. Currie,Mark Mayo,Mark Baker,Mark E. Cooper,Jian Li,Tony Velkov +13 more
TL;DR: The combination of polymyxin B and SERMs illustrated a synergistic activity against XDR Gram-negative pathogens, including highly poly myxin-resistant P. aeruginosa isolates, and represents a novel combination therapy strategy for the treatment of infections because of problematic XDR gram- negative pathogens.
Journal ArticleDOI
Diabetes: treating diabetic nephropathy-still an unresolved issue.
TL;DR: There is no clear-cut evidence showing that intensive glycaemic control reduces the risk of micro albuminuria and macroalbuminuria, but there is noclear-cutEvidence showing that it reduces doubling of serum creatinine levels or risk of death from kidney disease.
Journal ArticleDOI
Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus
Toshiaki Ohkuma,Min Jun,Anthony Rodgers,Mark E. Cooper,Paul Glasziou,Pavel Hamet,Stephen B. Harrap,Giuseppe Mancia,Michel Marre,Bruce Neal,Vlado Perkovic,Neil R Poulter,Bryan Williams,Sophia Zoungas,Sophia Zoungas,John Chalmers,Mark Woodward,Mark Woodward +17 more
TL;DR: The continuation of angiotensin-converting enzyme inhibitor-based therapy reduced the long-term risk of major clinical outcomes, irrespective of acute increase in creatinine, in diabetes mellitus patients randomly assigned to perindopril-indapamide or placebo.
Journal ArticleDOI
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
Sigrid C. van Steen,Mark Woodward,Mark Woodward,John Chalmers,Qiang Li,Michel Marre,Mark E. Cooper,Pavel Hamet,Giuseppe Mancia,Stephen Colagiuri,Bryan Williams,Diederick E. Grobbee,J. Hans DeVries +12 more
TL;DR: Clinical use of HGI in type 2 diabetes cannot currently be recommended, given the discordant results and uncertain relevance beyond HbA1c.